Biological
CNTO 328
CNTO 328 is a biological therapy with 5 clinical trials. Historical success rate of 100.0%.
Total Trials
5
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 4 completed trials
Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
25%(1 trials)
Phase Distribution
Ph phase_2
2
40%
Ph phase_1
3
60%
Phase Distribution
3
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
3(60.0%)
Phase 2Efficacy & side effects
2(40.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
80.0%
4 of 5 finished
Non-Completion Rate
20.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(4)
Terminated(1)
Detailed Status
Completed4
Withdrawn1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 13 (60.0%)
Phase 22 (40.0%)
Trials by Status
withdrawn120%
completed480%
Recent Activity
0 active trials
Showing 5 of 5
completedphase_1
A Study of CNTO 328 in Subjects With Metastatic Renal Cell Carcinoma
NCT00265135
completedphase_1
A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease
NCT00412321
completedphase_1
A Study of CNTO 328 in Patients With Metastatic Hormone-Refractory Prostate Cancer
NCT00401765
withdrawnphase_2
S0351, CNTO 328 in Treating Patients With Unresectable or Metastatic Kidney Cancer
NCT00311545
completedphase_2
S0354, Anti-IL-6 Chimeric Monoclonal Antibody in Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
NCT00433446
Clinical Trials (5)
Showing 5 of 5 trials
NCT00265135Phase 1
A Study of CNTO 328 in Subjects With Metastatic Renal Cell Carcinoma
NCT00412321Phase 1
A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease
NCT00401765Phase 1
A Study of CNTO 328 in Patients With Metastatic Hormone-Refractory Prostate Cancer
NCT00311545Phase 2
S0351, CNTO 328 in Treating Patients With Unresectable or Metastatic Kidney Cancer
NCT00433446Phase 2
S0354, Anti-IL-6 Chimeric Monoclonal Antibody in Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
All 5 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 5